CELLAVISION AB (publ) - Year-End Bulletin 2009

2010-02-12 - English

Third consecutive year of profitability


January - December

  • Net sales increased by 8 % to SEK 109.0 million (100.4)
  • The operating result increased to SEK 14.8 million (13.4)
  • Profit before income tax increased to SEK 14.2 million (13.1)
  • The net result per share amounted to SEK 1.16 (1.05)
  • Cash and cash equivalents amounted to SEK 22.0 million (19.6) by the end of the year
  • Gross profit was 70 % (63) during the year
  • Strengthened presence on markets in the US, Canada, and Japan
  • Strong initial sales of the new CellaVision® DM1200 analyzer in Europe and North America
  • CellaVision was awarded the SwedenBIO Award 2009

October - December

  • Net sales for the fourth quarter amounted to SEK 39.3 million (38.3)
  • The operating result amounted to SEK 7.5 million (7.1)

Important events after the end of the year

  • CellaVision expanded distribution channels in the US through an agreement with Beckman Coulter
  • The Board of Directors of CellaVision plans to apply for a listing on NASDAQ OMX Small Cap during the first half of 2010


  CellaVision in short






Q4 2009

Q4 2008

Year 2009

Year 2008

  Net sales





  Gross profit





  Operating result





  Profit before tax





  Cash flow







CEO's comment


It is very pleasing to look back at another year of profitability, says Yvonne Mårtensson, CEO of CellaVision. During the year we have continued to invest in our subsidiaries in the US, Canada and Japan by recruiting more personnel and enhancing market activities, making the company more visible and continuing the penetration of these important markets. For the first time in CellaVision history net sales were higher in North America than in Europe. Our new analyzer, the DM1200, was launched in Europe and Canada and will soon be available on the US market, and we have entered an agreement with an additional global distributor, Beckman Coulter. These are all steps towards strengthening our position as market leading in image analysis for hematology laboratories. We are well prepared for the challenges that await us in 2010 in our ambition for achieving continued growth.



For more information please contact:


Yvonne Mårtensson, CEO. Phone: +46 708 33 77 82, e-mail: yvonne.martensson@cellavision.se

Johan Wennerholm, CFO. Phone: +46 708 33 81 68, e-mail: johan.wennerholm@cellavision.se



Download the report by pressing the link below.

PDF version: CELLAVISION AB (publ) – Year-End Bulletin 2009

Subscribe to updates

It's possible to subscribe to CellaVision's press releases, financial information by e-mail and SMS.

Click here to register

Information request

Are you looking for some particular information about our company or our business?

Click here to get in touch


ABG Sundal Collier AB
Sten Gustafsson
+46 8 566 286 93

Pareto Securities AB
Christian Lee
+46 8 402 52 67


Access our Student Resources

To access this resource, please provide the following information about yourself.